Hypertension is a chronic disease that is controlled in the United States in only 34% of those taking antihypertensive medications. Because hypertension is a hemodynamic disorder, the patient's hemodynamic profile before and after medical intervention may assist in the decision and evaluation of ongoing antihypertensive therapy. There are several medication classes used in the management of hypertension and it is challenging at best for the clinician to determine the optimal therapeutic combination of medications for each patient. Physician perceptions and patient symptoms are examples of barriers affecting the management and control of hypertension. Impedance cardiography is a noninvasive monitoring technique that provides reliable and reproducible hemodynamic measurements. Three case studies are presented that illustrate how hemodynamic parameters were used to achieve hypertension control in the outpatient setting. 
B
lood pressure (BP) levels are determined by the interaction of the vascular, renal, hormonal, and sympathetic nervous system mechanisms 1 and hypertension (HTN) occurs when there is abnormal regulation of one or more of these systems. Hypertension affects more than 50 million individuals in the US and it is estimated that only 70% of those affected are aware of their condition. 2 In addition, only 59% of patients with HTN are treated with medications and only 34% achieve target BP Ͻ140/90 mm Hg. 2 Adequate HTN management requires combination therapy with two or more medications in the majority of patients. 2 Hypertension is a major risk factor in the development of ischemic heart disease (IHD), heart failure, kidney disease, and cerebrovascular disease leading to stroke. 2 Antihypertensive agents control BP and reduce the morbidity and mortality associated with HTN. Studies have indicated that even small reductions in systolic or diastolic BP result in 30% and 40% reductions in the risk of IHD and fatal stroke, respectively. 3 The classes of antihypertensive medication include diuretics, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers, ␤-adrenergic blockers, calcium channel blockers, and direct vasodilators. Because BP, and specifically mean arterial pressure (MAP), is the product of cardiac output (CO) and systemic vascular resistance (SVR), antihypertensive medications exert their effects by lowering CO, SVR, or both. From a hemodynamic standpoint, the ideal treatment regimen for HTN should lower BP while normalizing CO and SVR. Studies have shown that when medications appropriately target the underlying hemodynamic abnormalities in patients with HTN, BP control will be more effective. 4 The Seventh Report of the Joint National Committee (JNC-7) recommends the use of thiazide-type diuretics in the treatment regimen for the majority of patients. Diuretics are known to reduce CO by reducing the extracellular fluid volume, but also reduce SVR by reducing intracellular sodium and causing vascular smooth muscle cell relaxation. 5 Other agents that primarily affect CO are ␤-blockers and the non-dihydropyridine calcium channel blockers, diltiazem and verapamil. Drugs that have their primary action to reduce SVR include ACE inhibitors, angiotensin receptor blockers, ␣-adrenergic blockers, dihydropyridine calcium channel blockers, centrally acting ␣ 2 -agonists, and direct vaosdilators. 5 Dihydropyridine calcium channel blockers dilate the arterial resistance vessels without direct effects on cardiac systolic function or heart rate (HR). These agents act to relax blood vessels and improve myocardial blood flow while reducing workload. 6 Reasons that HTN is poorly controlled include a suboptimal medical regimen, medication intolerance, physi-cian perceptions about drug effectiveness, medication samples available in the office, and patient noncompliance. 7, 8 Historically, the choices of antihypertensive medications have been empirically based. Yakovlevitch and Black 9 found that the choice of drug regimen was the most important reason for suboptimal BP control in patients with resistant HTN. Berlowitz et al 10 concluded in their study that those patients who received more aggressive therapy had better BP control. Regardless of the reasons, poor control of HTN increases drug costs and frequency of physician visits. Aggressive treatment based on objective data has the potential to reduce these costs and thus resource utilization. 10, 11 Hypertension is a heterogeneous hemodynamic disorder and knowledge of the hemodynamic effects of medications in a particular patient can facilitate appropriate antihypertensive drug initiation and titration. Impedance cardiography (ICG) is a noninvasive technique that uses bioimpedance to determine hemodynamic measurements. The ICG provides the clinician with information that could only previously be obtained in the critical care unit of a hospital using a pulmonary artery catheter (PAC). In contrast, ICG allows the clinician access to reliable hemodynamic information in the outpatient as well as the hospital setting. The ICG aids in identifying the hemodynamic components of HTN, allowing initiation and titration of medications that act more effectively and result in fewer side effects. In studies using ICG, HTN specialists and generalists in the office setting have demonstrated improved BP control rates approaching 60% when ICG information is included in treatment decisions. 12, 13 Three case studies are presented that demonstrate how ICG parameters may be used to guide the prescription of antihypertensive agents.
Case Studies
Case One: Two-Medication Regime A 73-year-old white woman with a known history of HTN for 3.5 years presented to the physician's office for BP management. The primary diagnosis was HTN with secondary diagnoses of gastroesophageal reflux disease (GERD), osteoporosis, tremor, unspecified inflammatory polyarthropathy, and hyperlipidemia. Of significance is a previous history of a transient ischemic attack (TIA) 2 years earlier. Her symptoms at that time included sudden, temporary visual loss in one eye. Recent laboratory tests demonstrated a normal creatinine level of 0.8 mg/dL and total cholesterol was 174 mg.
Upon physical examination, her BP was 167/88 mm Hg, HR 62 beats/min, height 4 ft 11 inches, and weight was 139 lbs. She was taking perindopril 4 mg daily for HTN with her other medications of methotrexate, six tablets a week, celecoxib, omeprazole, folic acid, and calcium with vitamin D daily. She presented with symptoms of dizziness and stated she did not want to increase the dose of perindopril and preferred a change to a different antihypertensive medication. The ICG was performed with baseline and postinterventional parameters listed in Table 1 . Cardiac index (CI) was 2.0 L/min/m 2 , stroke index (SI) 32 mL/beat/m 2 , SVR index was 4364 dynes ⅐ sec ⅐ cm Ϫ5 ⅐ m 2 . and thoracic fluid content (TFC) was 23 kOhm Ϫ1 . Consistent with the patient's wishes, perindopril was discontinued and she was prescribed a single pill consisting of two antihypertensive compounds (amlodipine 5 mg/benazepril 10 mg) daily.
Approximately 1 month later, she was seen in the office with the symptoms of dizziness fully resolved and had no new symptoms. Her BP was143/73 mm Hg, much improved from pretreatment, and HR was 64 beats/min. Weight was 141 lbs, a 2-lb increase from previous visit and CI was 1.7 L/min/m 2 , a slight reduction from previous visit, and SVRI was 4094 dynes ⅐ sec ⅐ cm Ϫ5 ⅐ m 2 , still quite elevated. The TFC value increased to 25.4 kOhm Ϫ1 . The clinician doubled the dose of medication of amlodipine to 10 mg and benazepril to 20 mg daily.
The patient returned 6 weeks later without symptoms and BP was 120/59 mm Hg, HR 69 beats/min. She lost 3 lbs from the previous visit, weighing 138 lbs, and TFC had decreased to 22.7 kOhm
Ϫ1
. The CI had now increased to above pretreatment level at 2.3 L/min/ m 2 and the SVRI was significantly reduced to 2458 dynes ⅐ sec ⅐ cm Ϫ5 ⅐ m 2 . The patient was instructed to remain on this current medication regime and scheduled to return in 6 months.
Discussion
As noted, BP is the product of SVR and CO. This elderly patient presented with symptoms of dizziness and was found to have a markedly elevated SVRI and low CI. Elderly hypertensive patients tend to have high afterload as reflected by elevated SVRI. The hemodynamic findings 
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of elevated SVRI and reduced CI often reflect increased vascular and ventricular stiffness, altered ventricular contractility.
14 The renin-angiotensin-aldosterone system (RAAS) plays an important role in BP control. The goal of therapy is to decrease SVRI without compromising CO. The ACE inhibitors reduce BP through reduction in the formation of angiotensin II-a powerful vasoconstrictor that leads to salt retention and ventricular remodeling with hypertrophy. The ACE inhibitors decrease SVRI and promote natriuresis without a direct effect on CI or HR. 15 The TFC value for the patient trended upward from 23.0 to 25.4 kOhm Ϫ1 , but once dosages became therapeutic, hemodynamic balance was achieved through a reduction in SVR and increase in CI and subsequent reduction in TFC. The addition of a dihydropyridine calcium channel blocker to the ACE inhibitor further enhanced the desired vasodilatory effects.
In this case, ICG helped guide appropriate changes in medications. Physicians perceive that diuretics are less effective than other agents and ␤-blockers, calcium antagonists, and ACE inhibitors are less well tolerated due to side effects. 16 The patient's symptoms of dizziness were not due to excessive vasodilation and the hemodynamic information resulted in use of a different ACE inhibitor in combination with a second agent that lowers SVRI. At the subsequent visit, the hemodynamic data suggested that it was appropriate to double the calcium channel blocker in view of the persistently high afterload. 17 Findings of high SVRI in elderly patients with low or normal TFC and low CI may suggest the use of combination therapy with a calcium channel blocker and ACE inhibitor. Diuretics may not be advantageous in the elderly due to the susceptibility for dehydration as compared to younger age groups. 18 The ACE inhibitors and calcium channel blockers act as vasodilators, improve coronary and renal blood flow, and are useful in the reduction of hypertensive complications.
Results from the ALLHAT study focused on three different medication classes and their effects on the reduction of HTN complications. Both calcium channel blocking agents and ACE inhibitors reduced cardiovascular events including stroke. 19 In this patient's case, ICG identified a hemodynamic profile where the initiation and titration of the combination calcium channel blocker and ACE inhibitor might be expected to improve the hemodynamic status. The ICG-guided therapy resulted in BP control to goal without side effects and in three physician visits. The patient's perception that perindopril was causing side effects was addressed and yet the hemodynamic information provided the confidence to initiate a different agent within the same class. In so doing, this approach not only targeted the antihypertensive therapy to the hemodynamic abnormalities, but it helped reduce the risk of nonadherence to prescribed medications. 20 Achieving target BP levels with well-tolerated medications allowed for less frequent future visits and surveillance.
Case Two: Three-Medication Regime
A 68-year-old white man presented to the office with a 2-year history of HTN and chronic obstructive pulmonary disease (COPD). His only symptom at the time of the office visit was his usual dyspnea. The patient had been taking hydrochlorothiazide HCTZ 25 mg and atenolol 100 mg daily. His only additional medication was an inhaler that included the combination drugs ipratropium bromide and albuterol, taking two puffs four times a day. At physical examination, his height was 5 ft 9 inches, weight 163 lbs. His BP was 166/94 mm Hg with a HR of 59 beats/min. His creatinine level was normal at 1.1 mg/dL. The electrocardiogram revealed left atrial enlargement but was otherwise unremarkable. The ICG measurements at baseline and postintervention are listed in . On the basis of the stability of CI and TFC with significant improvement in BP and SVRI, this new medication regime was continued and he was scheduled to return for an evaluation in 1 month for consideration of reducing his ␤-blocker therapy.
Discussion
This case illustrates a common situation in patients with both COPD and HTN who may be on moderate doses of a ␤-blocker and taking albuterol, a ␤ 2 -adrenergic agonist. Atenolol is a cardioselective ␤ 1 antagonist; however, at higher doses it may have ␤ 2 receptor-blocking effects. The ␤ 1 receptors are responsible for effects on HR and con- Abbreviations as in Table 1 .
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tractility, whereas ␤ 2 receptors act peripherally to relax smooth muscle in arteries and bronchioles. 21 This patient's HR was below 60 beats/min, suggesting significant ␤ blockade. The ICG measurements were important in determining drug choice. The decision to initiate an ACE inhibitor, lisinopril, was the result of the elevated SVRI and the need to reduce SVRI without compromising CO. Because ACE inhibitors have both vasodilating and natriuretic actions, the patient did not experience fluid retention as evidenced by the stable TFC value. The CI increased slightly with increases in acceleration index (ACI) and velocity index (VI), measures that reflect improved cardiac performance that can accompany arterial vasodilation. The ACE inhibitors are valuable antihypertensive agents due to their impact on cardiovascular protection. Once BP control has been achieved, hemodynamic measurements will be helpful to monitor the effects of future reductions in the patient's ␤-blocker.
Case Three: Five-Medication Regime
The third case study is a 67-year-old white woman with a history of HTN for many years, reaching measurements up to 210/110 mm Hg. In addition to her HTN, she had osteoporosis and hyperlipidemia. She presented without symptoms, experiencing recent stress and anxiety related to elevated BP levels at home. Physical findings included a height of 5 ft, 2 inches, and weight of 133 lbs. Her BP was 206/103 mm Hg and HR was 62 beats/min. The examination was pertinent for an increase in A2 and presence of an S4 gallop without other findings. Her antihypertensiove medications included a combination of triamterene/HCTZ (37.5/25 mg) daily, atenolol 100 mg, doxazosin 8 mg, lisinopril 20 mg each daily, and clonidine 0.1 mg as need when systolic BP at home was more than 170 mm Hg. Her other medications included alendronate 70 mg a week and atorvastatin 10 mg at bedtime. Previous evaluation included a noninvasive renal artery study that was unremarkable, electrolytes, creatinine, blood urea nitrogen (BUN) levels, and a 24-h urine collection for catecholamines, vanillylmandelic acid (VMA), and metanephrines. All studies were normal except for the serum potassium of 2.7 mEq/L. The ICG was performed and baseline and postinterventional measurements are presented in Table 3 . At her initial visit, the CI was 2.0 L/min and SVRI was 5478 dynes ⅐ sec ⅐ cm Ϫ5 ⅐ m 2 . The TFC was 26.9 kOhm
Ϫ1
. In view of the significant elevation of SVRI and low CI, atenolol was decreased to 50 mg daily, lisinopril increased to 20 mg twice a day, clonidine started on regular dosing at 0.1 mg twice a day, and amlodipine was initiated at 10 mg daily. Doxazosin was decreased to 4 mg daily and due to the low potassium level, potassium replacement was started at 20 mEq three times a day for 5 days then twice a day. Two weeks after her initial visit, she called the office with symptoms of sedation and dry mouth and was seen by the office nurse with continued BP elevation. Her clonidine was stopped due to her side effects and amlodipine was increased to 10 mg twice a day. She returned to the office 1 month later and her BP was 143/68 mm Hg. She felt well and multiple home BP readings show that the BP ranged between 120 and 140/65 mm Hg, with rare episodes above 140/80 mm Hg. Hemodynamic parameters showed improvement in CI to 4.1 L/min with a reduction in SVRI to 1816 dynes ⅐ sec ⅐ cm Ϫ5 ⅐ m 2 . Because she was much improved on the multiple medication regimen, the decision was made to continue her current medications and re-evaluate the patient in 6 weeks. If BP remains controlled, consideration to the discontinuation of doxazosin will be given.
Discussion
This woman presented with uncontrolled BP on five antihypertensive medications. She was on atenolol, a drug with ␤-adrenergic receptor antagonist that reduces CI and may increase SVR. Clonidine affects the ␣-adenergic receptors near the vasomotor center of the nervous system. This medication will reduce BP through modest reductions in CI and HR and in long-term therapy reduces SVRI. Doxazosin is an ␣-blocker that reduces BP through a reduction in SVRI without affecting CI. 22 The patient's hemodynamic profile at initial visit revealed an extremely elevated SVRI and decreased CI. The ACE inhibitor and calcium channel blocker medication classes lower SVRI without causing a reduction in CI. The information obtained using ICG was important in the decision to increase the ACE inhibitor and add a calcium channel blocking agent while reducing atenolol and doxazosin. Concern over potential side effects may, in certain instances, act as a barrier to the up-titration of antihypertensive medications. In this case, ICG-derived hemodynamic data assisted the clinician by suggesting that the patient might tolerate higher doses of lisinopril as well as the addition of amlodipine. With ICG-guided therapy, CI increased and SVRI was reduced to achieve better cardiac performance and normotension. The vasodilation and improved CO that Abbreviations as in Table 1 .
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resulted may have contributed to the stable fluid status without increase in diuretic dose.
Conclusions
The ICG helps clinicians identify the specific mechanisms of high BP in a given patient and tailor a pharmacologic regimen to address the underlying hemodynamic status. This individualized approach to therapy may lead to fewer side effects from medications and reduce the number of office visits required to achieve BP control. The cases presented demonstrate that ICG provides useful objective data that aid decision-making in patients with HTN.
